检索结果-南通市图书馆

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies

Journal of Clinical and Translational Hepatology 2016年第2期4卷 143-150页

作者： Oluwatobi O.Ozoya Lubomir Sokol Samir Dalia Emergency and Trauma Center Tampa General HospitalTampaFLUSA Department of Hematological Malignancies H.Lee Moffitt Cancer CenterTampaFLUSA Oncology and Hematology Mercy Clinic JoplinJoplinMOUSA

Hepatitis B virus (HBV) infection remains an endemic disease in most parts of the world despite available prophylactic ***-Hodgkin's lymphoma is the most common hematological malignancy,and certain patients undergoing therapy are at increased risk of HBV ***,a monoclonal antibody,is well studied in HBV reactivation,but newer agents have been implicated as ***,we review novel agents suspected in HBV reactivation and effective strategies to prevent HBV *** years of literature were reviewed in order to better understand the reactivation rates of hepatitis B in patients with non-Hodgkin's ***-CD20 antibodies continue to be the main medications that can lead to HBV reactivation,and HBV reactivation rates have decreased with increased *** reactivation is uncommon when using other novel *** and lamivudine remain the agents of choice to prevent HBV reactivation in high risk *** conclusion,the immunosuppressive effect of NHL and its therapy provide a pathway for HBV reactivation,especially in patients treated with anti-CD20 *** many HBV positive patients are often excluded from clinical trials of novel agents in NHL,more aggressive post-market surveillance of new agents,welldesigned best practice advisories,and timely case reports are needed to reduce the incidence of HBV ***,large prospective investigations coupled with well-utilized best practice advisories need to be conducted to understand the impact of more potent novel NHL therapy on HBV reactivation.(C) 2016 The Second Affiliated Hospital of Chongqing Medical *** by XIA & HE Publishing *** rights reserved.

关键词： Hepatitis B virus HBV reactivation Non-Hodgkin's lymphoma Rituximab Anti-CD20 antibody best practice advisories

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：